FDA fast track status granted to iECURE neonatal OTC deficiency treatment
The US FDA has granted fast track designation for iECURE’s ECUR-506 for the treatment of neonatal onset ornithine transcarbamylase deficiency.
The US FDA has granted fast track designation for iECURE’s ECUR-506 for the treatment of neonatal onset ornithine transcarbamylase deficiency.
What's Your Reaction?
